Ovarian Cancer Coverage from Every Angle

Lucy Gilbert, MD, on Mirvetuximab Soravtansine Plus Bevacizumab for Platinum-Agnostic Ovarian Cancer

Posted: Monday, June 15, 2020

Lucy Gilbert, MD, of McGill University Health Center, discusses data showing mirvetuximab soravtansine plus bevacizumab is active with a favorable tolerability profile in patients with recurrent ovarian cancer regardless of platinum sensitivity.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.